WO2007089880A3 - Method to detect breast cancer cells - Google Patents

Method to detect breast cancer cells Download PDF

Info

Publication number
WO2007089880A3
WO2007089880A3 PCT/US2007/002716 US2007002716W WO2007089880A3 WO 2007089880 A3 WO2007089880 A3 WO 2007089880A3 US 2007002716 W US2007002716 W US 2007002716W WO 2007089880 A3 WO2007089880 A3 WO 2007089880A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
cancer cells
detect breast
detect
receptor expression
Prior art date
Application number
PCT/US2007/002716
Other languages
French (fr)
Other versions
WO2007089880A2 (en
Inventor
Vassilios Papadopoulos
Martine Culty
Original Assignee
Univ Georgetown
Vassilios Papadopoulos
Martine Culty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Vassilios Papadopoulos, Martine Culty filed Critical Univ Georgetown
Priority to AU2007211251A priority Critical patent/AU2007211251A1/en
Publication of WO2007089880A2 publication Critical patent/WO2007089880A2/en
Publication of WO2007089880A3 publication Critical patent/WO2007089880A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A quantitative method to detect variant and total peripheral-type benzodiazepine receptor expression is provided.
PCT/US2007/002716 2006-01-31 2007-01-31 Method to detect breast cancer cells WO2007089880A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007211251A AU2007211251A1 (en) 2006-01-31 2007-01-31 Method to detect breast cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76371006P 2006-01-31 2006-01-31
US60/763,710 2006-01-31

Publications (2)

Publication Number Publication Date
WO2007089880A2 WO2007089880A2 (en) 2007-08-09
WO2007089880A3 true WO2007089880A3 (en) 2007-11-15

Family

ID=38222452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/002716 WO2007089880A2 (en) 2006-01-31 2007-01-31 Method to detect breast cancer cells

Country Status (2)

Country Link
AU (1) AU2007211251A1 (en)
WO (1) WO2007089880A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc Use of highly parallel snp genotyping for fetal diagnosis
WO2012168697A1 (en) * 2011-06-06 2012-12-13 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
US10627389B2 (en) 2015-05-26 2020-04-21 Incelldx, Inc. Methods of assessing cellular breast samples and compositions for use in practicing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049316A2 (en) * 1998-03-25 1999-09-30 Georgetown University Medical Center Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049316A2 (en) * 1998-03-25 1999-09-30 Georgetown University Medical Center Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DE CREMOUX P ET AL: "Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 2000, vol. 6, no. 8, August 2000 (2000-08-01), pages 3117 - 3122, XP002449903, ISSN: 1078-0432 *
HAN ZEQIU ET AL: "Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression.", JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, vol. 23, no. 2-3, May 2003 (2003-05-01), pages 225 - 238, XP009089189 *
HARDWICK M ET AL: "Peripheral - type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 4, 15 February 1999 (1999-02-15), pages 831 - 842, XP002114583, ISSN: 0008-5472 *
HARDWICK M ET AL: "Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 NOV 2001, vol. 94, no. 3, 1 November 2001 (2001-11-01), pages 322 - 327, XP002449906, ISSN: 0020-7136 *
HARDWICK MATTHEW ET AL: "Peripheral-type benzodiazepine receptor (PBR) gene amplification in MDA-MB-231 aggressive breast cancer cells.", CANCER GENETICS AND CYTOGENETICS NOV 2002, vol. 139, no. 1, November 2002 (2002-11-01), pages 48 - 51, XP002449905, ISSN: 0165-4608 *
KURUMAJI A ET AL: "No association of two missense variations of the benzodiazepine receptor (peripheral) gene and mood disorders in a Japanese sample.", AMERICAN JOURNAL OF MEDICAL GENETICS 8 MAR 2001, vol. 105, no. 2, 8 March 2001 (2001-03-08), pages 172 - 175, XP002449910, ISSN: 0148-7299 *
LARA O ET AL: "Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 32, no. 10, October 2004 (2004-10-01), pages 891 - 904, XP004613157, ISSN: 0301-472X *
RING A ET AL: "Circulating tumour cells in breast cancer", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 5, no. 2, February 2004 (2004-02-01), pages 79 - 88, XP004808305, ISSN: 1470-2045 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date
AU2007211251A1 (en) 2007-08-09
WO2007089880A2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
WO2007089880A3 (en) Method to detect breast cancer cells
IL256247B (en) Activin-actrii antagonists and uses for increasing red blood cell levels
EP1999767B8 (en) Energy collection
EP1999811B8 (en) Fuel cells
EP1974391A4 (en) Passivating layer for photovoltaic cells
GB2440435B (en) Fuel cells
AP2954A (en) Devices and methods for detecting cells and other analytes
EP2109668A4 (en) Human cancer stem cells
ZA200805609B (en) Mesenchymal stem cells expressing TNF-α receptor
GB0608079D0 (en) Fuel cells
EP2421651A4 (en) Multiplex analysis of cells, particles, and other analytes
EP2033230A4 (en) Solar cells arrangement
GB0616045D0 (en) Blood cell separation
EP2008107A4 (en) Detection of steroid receptors on circulating carcinoma cells and treatment
EP2151004A4 (en) Electrochemical cells and methods for generating fuel
GB2440366B (en) Solar cells
EP2130255A4 (en) Corrosion-resistant interconnects for fuel cells
PL2191006T3 (en) Methods for assaying alpha-l-iduronidase enzymatic activity
WO2008078729A1 (en) Method for improving dissolution property
EP2149170A4 (en) Membraneless fuel cell and method of operating same
EP1715041A4 (en) Method of detecting cancer cell acquiring drug-resistance
GB0702007D0 (en) Anaerobic digester
GB0424877D0 (en) Energy resolved computer tomography
CA118203S (en) Straw chopper
WO2010065776A3 (en) Identification of neuroprotective agents using pro-inflammatory human glial cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007211251

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007211251

Country of ref document: AU

Date of ref document: 20070131

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 07717158

Country of ref document: EP

Kind code of ref document: A2